[Study of specific targeting cytotoxicity mediated by anti-CD(3)/anti-CD(20) Diabody].
OBJECTIVE
To study the specific targeting cytotoxicity mediated by an anti-CD(3)/anti-CD(20) diabody.


METHODS
The diabody was purified by affinity chromatography and identified by Western blot assay, size exclusion chromatography, FACS and rosetting assay; the effect of the anti-CD(3)/anti-CD(20) diabody mediated lysis of CD(20)-expressing tumor cells was assayed by (51)Cr release assay in vitro and by human B cell tumor nude mice xenograft model in vivo.


RESULTS
The anti-CD(3)/anti-CD(20) diabody could bind both Jurkat cells (CD(3)(+)) and Daudi cells (CD(20)(+)) and appeared to be potent in targeting activated peripheral blood mononuclear cell (PBMC) to lyse Daudi cells in vitro. Furthermore, it inhibited tumor growth and prolonged the survival of mice bearing xenografted Raji cells.


CONCLUSIONS
The diabody proved to be a potent agent for targeting peripheral blood lymphocytes to lyse CD(20) antigen expressing tumor cells in vitro and in vivo.
Xiong
D
D
State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin 300020, China.
Shao
X
X
Yang
C
C
Xu
Y
Y
Liu
H
H
Han
J
J
Peng
H
H
Yang
M
M
Zhu
Z
Z
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D017252:CD3 Complex / Q000276:immunology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D006801:Humans; D019169:Jurkat Cells; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
D018033:Antibodies, Bispecific; D018951:Antigens, CD20; D017252:CD3 Complex